Abdul Aneez Cheekylodan CK, Sudeep Mohapatra and Asma Patel
Cisatracurium is a novel, intermediate-lasting neuromuscular blocking medication that belongs to the benzylisoquinolinium class and does not cause depolarization. It serves as a stereoisomer as atracurium having around three to four times the potency of atracurium. At doses up to 0.4mg/kg (8xED95), cisatracurium does not produce histamine release and is linked with greater stability of hemodynamics than atracurium. A 0.15mg/kg (3xED95) intubating dose is advised. High Comparing atracurium to cisatracurium at same doses, most previous clinical investigations have found that atracurium has been more efficacious than cisatracurium at the same dose (2ED95). Raising the daily intake of cisatracurium from ED95 (0.1mg/kg) to ED95 (0.2mg/kg) or ED95 (0.3mg/kg) has been proven in a small number of investigations to result in greater neuromuscular blockage and better cardiovascular stability without a noticeable increase in histamine release. Therefore, the current study was conducted to examine the effects of cisatracurium at 2 ED95 and 4 ED95 on intubating circumstances and hemodynamic stability.
Pages: 01-06 | 111 Views 36 Downloads